Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT06429449
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: Navitoclax Dose Level 1Drug: Navitoclax Dose Level -1Drug: Navitoclax Dose Level 0Drug: Navitoclax Dose Level 2Drug: Venetoclax Dose Level -1Drug: Venetoclax Dose Levels 0 to 2Drug: CladribineDrug: Cytarabine (Cladribine Low Dose Cytarabine Backbone)Drug: Cytarabine (CLAG-M Backbone)Drug: MitoxantroneDrug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT06007911
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 90
- Registration Number
- NCT05848687
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Ayman H Qasrawi
- Registration Number
- NCT05330377
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Conditions
- Acute Biphenotypic LeukemiaMixed Phenotype Acute LeukemiaRelapsed Acute Myeloid LeukemiaRelapsed Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid LeukemiaRelapsed Acute Biphenotypic LeukemiaRelapsed Myeloid NeoplasmRefractory Acute Biphenotypic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRefractory Myeloid Neoplasm
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT04797767
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CladribineDrug: CyclosporineDrug: CytarabineBiological: FilgrastimProcedure: Hematopoietic Cell TransplantationDrug: MitoxantroneDrug: IdarubicinDrug: Mycophenolate MofetilDrug: FludarabineDrug: Mycophenolate SodiumRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195945
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.